(Q38084817)

28 August 2017

title

Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers (English)

1 reference

Rosamonde Elizabeth Banks

28 August 2017

1 reference

5

1 reference

28 August 2017

4

Peter J Selby

0 references

Margaret A Knowles

2

object named as

Margaret A Knowles

0 references

author name string

Steven L Wood

1

1 reference

28 August 2017

Douglas Thompson

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

26 February 2013

1 reference

28 August 2017

published in

Nature Reviews Urology

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

206-218

1 reference

Urinary-peptide excretion by patients with and volunteers without diabetes

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Molecular alterations during progression of prostate cancer to androgen independence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Basic research in kidney cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Molecular pathways of urothelial development and bladder tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Clinical urinary peptidomics: learning to walk before we can run.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Comprehensive human urine standards for comparability and standardization in clinical proteome analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Established and emerging markers of kidney function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Analysis of the variability of human normal urine by 2D-GE reveals a “public” and a “private” proteome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urine proteomics for profiling of human disease using high accuracy mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Exploring the hidden human urinary proteome via ligand library beads

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

A comprehensive map of the human urinary proteome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Identification and proteomic profiling of exosomes in human urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Mapping intact protein isoforms in discovery mode using top-down proteomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

31 March 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Health care spending, social policy, public health, and life expectancy: what cancer outcomes can tell us beyond treatment efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urine biomarkers in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Senescence-associated exosome release from human prostate cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Discovery and validation of urinary biomarkers for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Mesenchymal to epithelial transition in the human ovarian surface epithelium focusing on inclusion cysts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Molecular screening for bladder cancer: progress and potential.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Characterization of ADAM28 as a biomarker of bladder transitional cell carcinomas by urinary proteome analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Bikunin loss in urine as useful marker for bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Profilin 1 is a potential biomarker for bladder cancer aggressiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Searching cell-secreted proteomes for potential urinary bladder tumor markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Systematic quantification of peptides/proteins in urine using selected reaction monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomics analysis of bladder cancer exosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary biomarker profiling in transitional cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Novel agents in renal carcinoma: a reality check

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

14-3-3 proteins as signaling integration points for cell cycle control and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary biomarkers for the early diagnosis of kidney cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

A hyphenated microLC-Q-TOF-MS platform for exosomal lipidomics investigations: application to RCC urinary exosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Human urine biomarkers of renal cell carcinoma evaluated by ClinProt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Precipitating antigens of the normal human prostate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Commercial immunoassays in biomarkers studies: researchers beware!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

The journey to regulation of protein-based multiplex quantitative assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Randomized clinical trials with biomarkers: design issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantifying the added value of a diagnostic test or marker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Quantifying the accuracy of a diagnostic test or marker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Statistical methods for test and biomarker evaluation studies: a clinical chemistry series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Use of urinary biomarkers for bladder cancer surveillance: patient perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.24

Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma

31 March 2020

1 reference

12 December 2020

Proteomic analysis of prostate cancer metastasis-derived prostasomes

1 reference

12 December 2020

Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility

1 reference

12 December 2020

Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10)

1 reference

12 December 2020

Declining mortality from bladder cancer in Europe

1 reference

12 December 2020

Prostate cancer management

1 reference

12 December 2020

Analysis of prostate cancer by proteomics using tissue specimens

1 reference

12 December 2020

Screening for prostatic carcinoma with prostate specific antigen

1 reference

12 December 2020

Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.

1 reference

12 December 2020

Regulatory perspective on translating proteomic biomarkers to clinical diagnostics

1 reference

12 December 2020

Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.24

1 reference

Dimensions Publication ID

28 August 2017

1011088425

0 references

1 reference